Influence of ethnic origin and sex on the pharmacokinetics of clazosentan

Journal of Clinical Pharmacology

Volumn 47, Issue 11, 2007, Pages 1374-1380

  Van Giersbergen, Paul L M ^a   Gunawardena, Kulasiri A ^b   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b Chiltern International Ltd   (United Kingdom)

Author keywords

Clazosentan; Endothelin; Ethnic origin; Pharmacokinetics; Sex

Indexed keywords

CLAZOSENTAN; METOCLOPRAMIDE; PARACETAMOL;

ADULT; ARTICLE; BACKACHE; BLOOD ANALYSIS; BLOOD SAMPLING; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ETHNICITY; FEMALE; FLUSHING; HOT FLUSH; HUMAN; JAPANESE; MALE; NAUSEA; NORMAL HUMAN; NOSE CONGESTION; OPEN STUDY; SEX DIFFERENCE; SIDE EFFECT; SOMNOLENCE; SORE THROAT; SYSTOLIC BLOOD PRESSURE; VOMITING;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; DIOXANES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PYRIDINES; PYRIMIDINES; RECEPTORS, ENDOTHELIN; SEX FACTORS; SULFONAMIDES; TETRAZOLES;

EID: 35448954911     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007307337     Document Type: Article

References (20)

1. Yanagisawa M., Kurihara H., Kimura S., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988 ; 332: 411-415.
2. Stewart DJ, Levy RD, Cernacek P., Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med. 1991 ; 114: 464-469.
3. Masaoka H., Suzuki R., Hirata Y., Emori T., Marumo F., Hirakawa K. Raised plasma endothelin in aneurysmal subarachnoid haemorrhage. Lancet. 1989 ; 2: 1402.
4. Lüscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation. 2000 ; 102: 2434-2440.
5. Roux S., Breu V., Giller T., et al. Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther. 1997 ; 283: 1110-1118.
6. Vajkoczy P., Meyer B., Weidauer S., et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled multicenter Phase IIa study. J Neurosurg. 2005 ; 103: 9-17.
7. Dorsch Nwc, King MT A review of cerebral vasospasm in aneurysmal subarachnoid haemorrhage. J Clin Sci. 1994 ; 1: 19-26.
8. van Giersbergen Plm, Dingemanse J. Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist. Eur J Clin Pharmacol. 2007 ; 63: 151-158.
9. Bjornsson TD, Wagner JA, Donahue SR, et al. A review and assessment of potential sources of ethnic differences in drug responsiveness. J Clin Pharmacol. 2003 ; 43: 943-967.
10. Johnson JA Predictability of the effects of race or ethnicity on pharmacokinetics of drugs. Int J Clin Pharmacol Ther. 2000 ; 38: 53-60.
11. Xie H-G., Kim RB, Wood Ajj, Stein CM Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol. 2001 ; 41: 815-850.
12. King JT Jr. Epidemiology of aneurysmal subarachnoid hemorrhage. Neuroimaging Clin N Am. 1997 ; 7: 659-668.
13. Kongable GL, Lanzino G., Germanson TP, et al. Gender-related differences in aneurysmal subarachnoid hemorrhage. J Neurosurg. 1996 ; 84: 43-48.
14. Macdonald LR, Kakarieka A., Mayer S., et al. Prevention of cerebral vasospasm after aneurysmal subarachnoid hemorrhage with clazosentan, an endothelin receptor antagonist. Abstract presented at: 9th International Conference on Cerebral Vasospasm; 2006 ; June 27-30, 2006 ; Istanbul, Turkey.
15. Gough K., Hutchison M., Keene O., et al. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Inf J. 1995 ; 29: 1039-1048.
16. Dang MT, Hambleton J., Kayser SR The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother. 2005 ; 39: 1008-1012.
17. Garcia D., Regan S., Crowther M., Hughes RA, Hylek EM Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest. 2005 ; 127: 2049-2056.
18. Dingemanse J., van Giersbergen PLM. Influence of mild liver impairment on the pharmacokinetics of tezosentan, a drug excreted unchanged into bile. Br J Clin Pharmacol. 2003: 57 ; 344-348.
19. Ito S., Ieiri I., Tanabe M., Suzuki A., Higuchi S., Otsubo K. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics. 2001: 11 ; 175-184.
20. Kaptain GJ, Lanzino G., Kassell NF Subarachnoid hemorrhage: epidemiology, risk factors, and treatment options. Drugs Ageing. 2000 ; 17: 183-199.